Combined with the results of our study, we speculate that the percentage of CD8+MAIT cells in the peripheral blood of patients with NSCLC may be related to the sensitivity to immunotherapy and may serve as a predictive biomarker for immunotherapy efficacy in patients with lung cancer. This evidence concerns the gene CD8A and non-small cell lung carcinoma.